Modified MMAF

Modified MMAF

• CAS Number: 1352202-47-1
• UNSPSC Description: Modified MMAF, an ADC cytotoxin, can be used in the synthesis of Antibody-drug Conjugate (ADC). Modified MMAF can be used for the targeted research of cancer[1].
• Target Antigen: Microtubule/Tubulin
• Type: Reference compound
• Related Pathways: Cell Cycle/DNA Damage;Cytoskeleton
• Applications: Cancer-programmed cell death
• Field of Research: Cancer
• Assay Protocol: https://www.medchemexpress.com/modified-mmaf.html
• Solubility: 10 mM in DMSO
• Smiles: O=C(N1CCCCO1)[C@@H](NC([C@H](C)[C@H]([C@@]2([H])N(CCC2)C(C[C@@H](OC)[C@H]([C@@H](C)CC)N(C)C([C@H](C(C)C)NC([C@@H](NC)C(C)C)=O)=O)=O)OC)=O)CC3=CNC4=CC=CC=C34
• Molecular Weight: 840.10
• References & Citations: [1]Polson AG, et al. Antibody-drug conjugates for the treatment of non-Hodgkin's lymphoma: target and linker-drug selection [published correction appears in Cancer Res. 2010 Feb 1;70(3):1275. Slaga, Dion S [added]]. Cancer Res. 2009;69(6):2358-2364.|[2]Doronina SO, et al. Enhanced activity of monomethylauristatin F through monoclonal antibody delivery: effects of linker technology on efficacy and toxicity. Bioconjug Chem. 2006;17(1):114-124.
• Shipping Conditions: Room temperature
• Clinical Information: No Development Reported